The Viral Hemorrhagic Fever Consortium is delighted to announce that Dr. Donald S. Grant, Chief Physician of the Lassa Fever Program at Kenema Government Hospital in Sierra Leone, has obtained a Master of Science in Public Health degree from the Tulane School of Public Health and Tropical Medicine. Dr.
On Friday, December 18, 2015, the Sierra Leonean government commemorated “outstanding persons/organizations in the fight against Ebola.” An award ceremony and reception were hosted by His Excellency President Ernest Bai Koroma in Freetown. Among the awardees were members of the Viral Hemorrhagic Fever Consortium’s (VHFC) team from the Kenema Government Hospital (KGH).
In a large multi-disciplinary collaboration, researchers from the Viral Hemorrhagic Fever Consortium (VHFC) have published key findings on Lassa virus (LASV) evolution. The study, published in the August 2015 edition of Cell, shares unique insights into the origins and evolutionary dynamics of LASV.
According to an independent field validation study recently published in The Lancet, a new 15 minute rapid Ebola test co-developed by VHFC researchers from Tulane University and Corgenix Medical Corporation is as accurate as much more time consuming traditional lab testing for the disease.
In a large collaboration between Kenema Government Hospital, Harvard University, Broad Institute, Tulane University, Edinburgh University, the Centers for Disease Control, United States Army Medical Research Institute of Infectious Diseases, and others, the Viral Hemorrhagic Fever Consortium has published a paper in Cell detailing the epidemiology, transmission, and evolution of Ebola virus ove
Corgenix, together with Tulane University, Autoimmune Technologies, Zalgen Labs, and other VHFC partners have received approval for their bedside 15-minute ReEBOV Ebola virus test. This will allow patients to be identified and cared for as quickly as possible.
Corgenix Medical Corporation, a VHFC partner, and worldwide developer of diagnostics test kits, has been awarded two grants totaling $818,000 to advance the development of an Ebola rapid diagnostic test kit.